Skip to main content
OpenTrials
Completed

NCT Number: NCT07229131

Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses

The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

30 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.

Guangzhou, China

About this study

The main objective of this study is to assess efficacy of the product on skin translucency after 84 days of product compared to a placebo. The study will also evaluate the effect of the product on different skin parameters (radiance, firmness, elasticity, skin barrier function, skin pH, blood flow) with different instruments. The quality of life and the improvement of skin properties will also be collected with questionnaires completed by the subjects. Finally, the safety of this product will be assessed by collecting all adverse events that might occur during the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy women.
  • Chinese.
  • Age: in each group of products
  • 50% of subject having 30 to 45 years old
  • 50% of subject having 46 to 60 years old
  • Phototype: II to IV.
  • Subject with dull skin from grade 3 to 7 on skin dullness 9 points scale.
  • Subject exposed to high air pollution up to 2 to 3 hours per day (traffic roads, cigarette smoke, dusts or small particles).
  • Subject who accepts daily exposition to blue light (mobile phone, Ipad, laptop or get exposure to LED light) at home (at least 2h).
  • Subject with at least 1 spot on the face.
  • Subject with BMI ≤ 30
  • Subject, psychologically able to understand the study related information and to give a written informed consent.
  • Subject having given freely and expressly her informed consent.
  • Subject agreeing to not change her alimentary and cosmetic habits on the studied area during the study.

Exclusion criteria

In term of population :

  • Pregnant or nursing woman or planning a pregnancy during the study.
  • Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
  • Minor subject.
  • Major subject who is under guardianship or who is not able to express her consent.
  • Subject in a social or sanitary establishment.
  • Subject suspected to be non-compliant according to the investigator's judgment.

In term of associated pathology :

  • Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
  • Subject suffering from a severe or progressive disease.
  • Subject with known history of or suffering from skin disease that may interfere with evaluation of the study results and/or subject safety.
  • Subject having history of severe allergy or anaphylactic shock including known risk of hypersensitivity to one of the components of the composition of the product

Related to previous or ongoing treatment :

  • Subject undergoing a topical treatment on the test area or a systemic treatment:
  • anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
  • corticosteroids during the 2 previous weeks and during the study;
  • retinoids and/or immunosuppressors during the 3 previous months and during the study;
  • any medication stabilized for less than one month.
  • Subject having started or changed her oral contraceptive or any other hormonal treatment during the three previous months.
  • Subject having done facial skin care like peeling, mask… during the previous 2 weeks and during the study.
  • Subject having used oral nutritional supplements and/or vitamin supplementation during the previous month and during the study

In term of lifestyle :

  • Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
  • Subject having used topical products containing actives substances during the previous 2 weeks and during the study
  • Subject planning to change her life habits during the study.
  • Subject with unstable eating habits or planning to change them during the study
  • Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 5 cigarettes per day).

Treatment and study plan

Acerola Juice Powder 1200 mg/day

Dietary Supplement

4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin

Acerola Juice Powder 600 mg/day

Dietary Supplement

4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin

Placebo

Other

4 capsules per day, each capsule containing 400 mg of maltodextrin

Primary outcomes

  1. Change from baseline on skin translucency parameter Alpha at 84 days

    Time frame: From enrollment to 84 days of supplementation

    The skin translucency parameter Alpha is measured with translucency meter

Secondary outcomes

  1. Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days

    Time frame: From enrollment to 28 days of supplementation

    The skin translucency parameters Alpha, Area and Kis are measured with translucency meter

  2. Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days

    Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation

    Skin complexion radiance measured with Colorface®

  3. Change from baseline on pigment spot at 14, 28, 56 and 84 days

    Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation

    Pigment spot measured with Colorface®

  4. Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Skin firmness, elasticity and fatigability measured with Cutometer®

  5. Change from baseline on Trans Epidermal Water Loss at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Trans Epidermal Water Loss measured with Tewameter®

  6. Product safety

    Time frame: From enrolment to 84 days

    Safety assessed by the collection of adverse events and concomitant treatments throughout the study

Other outcomes

  1. Change from baseline on skin pH at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Skin pH measured with pH meter

  2. Change from baseline on blood flow at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Blood flow measured with Laser speckle blood flow imager®

  3. Change from baseline on subject quality of life at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Quality of life assessed using the questionnaire SF-12 completed by the subjects

  4. Change from baseline on subject satisfaction at 28 and 84 days

    Time frame: From enrollment to 28 and 84 days of supplementation

    Subject satisfaction assessed with a subjective evaluation questionnaire developed by the Sponsor completed by the subjects

Sponsors and collaborators

Lead sponsor

Diana SAS

Industry

Collaborators

  • Eurofins Dermscan Pharmascan

Registry information

Official study title

Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses: A Double-blind, Randomised, Placebo-controlled Study.

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 14, 2025
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.